Evolus reported Q2 2026 revenue of $84.1 million, up 21% year-over-year, and raised full-year 2026 guidance following the beat. The neuromodulator and device company achieved break-even on an adjusted EBITDA basis, extending its streak of profitability quarters as gross margins held steady.
Jeuveau continues to drive growth across the toxin portfolio, with the company maintaining pricing discipline and market share gains in the U.S. aesthetic market. Perceptive Advisors LLC acquired a new stake in Evolus during the quarter, signaling institutional confidence in the turnaround narrative.